Use of administrative claims data in observational studies of antirheumatic medication effects on pregnancy outcomes: a scoping review protocol

被引:1
|
作者
Tharmarajah, Shenthuraan [1 ]
Guilcher, Sara [1 ,2 ]
Santhireswaran, Araniy [1 ]
Mccarthy, Lisa [1 ,2 ,3 ]
Mahendira, Dharini [4 ]
Berger, Howard [5 ]
Tadrous, Mina [1 ,3 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada
[2] Trillium Hlth Partners, Inst Better Hlth, Mississauga, ON, Canada
[3] Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada
[4] Univ Toronto, Dept Med, Div Rheumatol, Toronto, ON, Canada
[5] St Michaels Hosp, Dept Obstet & Gynecol, Toronto, ON, Canada
关键词
drug safety; maternal-fetal medicine; pregnancy; rheumatic diseases; scoping review; GUIDELINE; DISEASES; DRUGS; WOMEN;
D O I
10.11124/JBIES-23-00039
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective:The primary objective of this review is to examine which disease-modifying antirheumatic drugs (DMARDs) and biologics used to treat pregnant individuals with rheumatic conditions have been reported in observational studies using population-based health administrative data. The secondary objective is to describe which adverse pregnancy outcomes (both maternal and neonatal) have been reported, their definitions, and corresponding diagnostic and/or procedural codes.Introduction:Pregnant individuals are typically excluded from drug trials due to unknown potential risks to both the pregnant person and fetus, leaving most antirheumatic drugs understudied for use in pregnancy. Despite these substantial knowledge gaps, most pregnant individuals continue to be maintained on antirheumatic medications due to the benefits generally outweighing the risks. In contrast to previous systematic reviews of findings from randomized trials, our scoping review aims to leverage this real-world data to generate real-world evidence of antirheumatic drug safety during pregnancy.Inclusion criteria:Articles must report on observational studies using population-based health administrative data from pregnant individuals with rheumatic conditions (rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, and psoriatic arthritis) receiving antirheumatic drug therapy (DMARDs and biologics). Randomized trials, reviews, case studies, opinion pieces, and abstracts will be excluded.Methods:Electronic databases (MEDLINE [Ovid], Embase [Ovid], CINAHL [EBSCOhost]) and gray literature (OpenGrey, Health Services Research Projects in Progress, World Health Organization Library, and Google Scholar) will be searched for relevant evidence. Search terms will combine 4 concepts: rheumatic diseases, drug therapy, pregnancy, and health care administrative data. Identified articles will be independently screened, selected, and extracted by 2 researchers. Data will be analyzed descriptively and presented in tables.Review registration:Open Science Framework https://osf.io/5e6tp
引用
收藏
页码:106 / 115
页数:10
相关论文
共 50 条
  • [1] Use of healthcare administrative claims data in observational studies of antirheumatic drug effects on pregnancy outcomes: A scoping review
    Tharmarajah, Shenthuraan
    Santhireswaran, Araniy
    Ameeriar, Yasmeen
    McCarthy, Lisa M.
    Mahendira, Dharini
    Berger, Howard
    Tadrous, Mina
    Guilcher, Sara J. T.
    PLOS ONE, 2025, 20 (03):
  • [2] Use of Healthcare Administrative Claims Data in Observational Studies of Antirheumatic Drug Effects on Pregnancy Outcomes: A Scoping Review
    Tharmarajah, Shenthuraan
    Santhireswaran, Araniy
    Ameeriar, Yasmeen
    Guilcher, Sara
    McCarthy, Lisa
    Mahendira, Dharini
    Berger, Howard
    Tadrous, Mina
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 489 - 489
  • [3] Fracture definitions in observational osteoporosis drug effects studies that leverage healthcare administrative (claims) data: a scoping review
    N. Konstantelos
    A. M. Rzepka
    A. M. Burden
    A. M. Cheung
    S. Kim
    P. Grootendorst
    S. M. Cadarette
    Osteoporosis International, 2022, 33 : 1837 - 1844
  • [4] Fracture definitions in observational osteoporosis drug effects studies that leverage healthcare administrative (claims) data: a scoping review
    Konstantelos, N.
    Rzepka, A. M.
    Burden, A. M.
    Cheung, A. M.
    Kim, S.
    Grootendorst, P.
    Cadarette, S. M.
    OSTEOPOROSIS INTERNATIONAL, 2022, 33 (09) : 1837 - 1844
  • [5] Strategies for measuring prescription medication switching with pharmacy claims data: a scoping review protocol
    Harris, Daniel A.
    Bouck, Zachary
    Tricco, Andrea C.
    Cadarette, Suzanne M.
    Iaboni, Andrea
    Bronskill, Susan E.
    JBI EVIDENCE SYNTHESIS, 2021, 19 (09) : 2441 - 2456
  • [6] Pregnancy Outcomes and Maternal Morbidity Using Administrative Claims Data in the US
    Naidoo, Nivantha
    Hamid, Asma
    Nowacki, Gregoire
    Tagliabue, Stefano
    Raad, Hanaya
    Medina, Patricia
    Furegato, Martina
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 475 - 475
  • [7] Pregnancy Outcomes Among Patients with Vasculitis Using Administrative Claims Data
    Rector, Amadeia
    Simard, Julia
    Shaw, Gary
    Horomanski, Audra
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4801 - 4803
  • [8] Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy
    Luke E. Grzeskowiak
    Andrew L. Gilbert
    Janna L. Morrison
    European Journal of Clinical Pharmacology, 2012, 68 : 459 - 467
  • [9] Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy
    Grzeskowiak, Luke E.
    Gilbert, Andrew L.
    Morrison, Janna L.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (05) : 459 - 467
  • [10] Fracture outcome definitions in observational osteoporosis drug effects studies: a scoping review protocol
    Konstantelos, Natalia
    Rzepka, Anna M.
    Cadarette, Suzanne M.
    JBI EVIDENCE SYNTHESIS, 2022, 20 (03) : 907 - 916